Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott reported 2Q26 sales up 13.0% (reported) and 4.8% (comparable), with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to $5.45–$5.60 (from $5.38–$5.58) while reaffirming 2026 comparable sales growth of 6.5%–7.5%. Abbott also returned $2.1B to shareholders in the quarter via dividends and share repurchases, supporting a constructive outlook into 2H26.

Analysis

This reads as a mix-quality improvement story more than a clean operating inflection. The commercial engine is becoming more recurring and less cyclical, but the close of a large diagnostics acquisition means the reported uplift still carries meaningful amortization, integration and legal noise; that caps immediate margin enthusiasm even if EPS guidance steps up. In practice, that usually supports a higher floor for the multiple, not a sharp expansion, unless management can show the acquired assets are accretive to free cash flow rather than just headline sales.

Relative winners are Abbott’s own device franchises and incumbents in adjacent care pathways that benefit from embedded workflows; relative losers are smaller rivals trying to displace an incumbent platform in electrophysiology, structural heart and diabetes. The CRC-screening signal is more important than it looks: guideline reinforcement tends to harden payer policy and physician habit for 6-18 months, which makes it harder for blood-based or newer screening entrants to win share without a superior clinical step-up. That is a slow-burn moat effect, not a one-quarter pop.

The main risk is that the raised earnings view is being pulled forward by financial engineering and mix, while underlying organic growth still needs to prove it can hold in the mid-single digits without new product surprises. Falsifiers include organic comparable sales slipping back below ~4%, any 200+ bp deceleration in medical devices, or delays around the pending LAA/IVL catalysts. Near term the stock can grind higher, but the cleaner entry is on weakness or via defined-risk upside structures rather than chasing strength.

Key Decisions for Investors

• Buy ABT on a 2-3% post-print pullback; use a 3-6 month 25-delta call spread to limit premium while keeping upside into the next catalyst window.
• Pair long ABT / short MDT for a 1-3 month relative-value trade: Abbott has better visible growth dispersion across devices + diagnostics, while MDT remains more dependent on slower, less diverse end markets.
• If ABT gaps up hard on the print, sell into the move and wait for confirmation that organic comps stay above ~4% and margin conversion improves; otherwise the rerating risk is capped by amortization and integration drag.
• Set an alert to add ABT only if management reaffirms H2 organic growth and free cash flow conversion after the conference call; if either weakens, treat the earnings raise as largely non-core and fade the move.